Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA1 | Q92743 | 16/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | CTSV | O60911 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19745347 | 1.00 | HTRA1 (0.59) | HTRA1TSHRCTSLCTSSCTSK | |
| SCHEMBL30335180 | 1.00 | HTRA1 (0.59) | HTRA1TSHRCTSLCTSSCTSK | |
| SCHEMBL2687419 | 1.00 | HTRA1 (0.59) | HTRA1TSHRCTSLCTSSCTSK | |
| SCHEMBL21536106 | 0.90 | HTRA1 (0.58) | HTRA1CTSLCTSSCTSK | |
| SCHEMBL28979527 | 0.90 | HTRA1 (0.58) | HTRA1CTSLCTSSCTSK | |
| SCHEMBL21487952 | 0.86 | HTRA1 (0.63) | HTRA1 | |
| SCHEMBL21487954 | 0.86 | HTRA1 (0.63) | HTRA1 | |
| SCHEMBL21535973 | 0.86 | HTRA1 (0.60) | HTRA1 | |
| SCHEMBL24012373 | 0.85 | HTRA1 (0.62) | HTRA1 | |
| SCHEMBL19745250 | 0.85 | HTRA1 (0.69) | HTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563033-B | Aliphatic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10730832-B2 | Aliphatic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3472130-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017222917-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730832-B2 | Aliphatic prolinamide derivatives | HTRA1, ALDH1A2, PREP | HTRA1 1/4885TSHR 1713/4885CTSL 475/4885 |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, PREP | HTRA1 1/4885TSHR 1713/4885CTSL 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.